Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 16, 2009, Pages 6820-6825

  Reiman, Eric M ^a,b,c,d   Chen, Kewei ^a,d,e,f   Liu, Xiaofen ^a,d   Bandy, Daniel ^a,d   Yu, Meixiang ^a,d,f   Lee, Wendy ^a,d   Ayutyanont, Napatkamon ^a,d   Keppler, Jennifer ^a,d   Reeder, Stephanie A ^a,d   Langbaum, Jessica B S ^a,d   Alexander, Gene E ^d,g   Klunk, William E ^h   Mathis, Chester A ^h   Price, Julie C ^h   Aizensteini, Howard J ^h   DeKosky, Steven T ^h,j   Caselli, Richard J ^d,i  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

^g University of Arizona   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Apolipoprotein E; Pittsburgh compound B pet

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CEREBELLUM CORTEX; CINGULATE GYRUS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GENE DOSAGE; GENETIC PREDISPOSITION; GENETIC RISK; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL PARAMETERS; TEMPORAL CORTEX; BRAIN MAPPING; GENETICS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; BRAIN MAPPING; COGNITION; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 66149084048     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900345106     Document Type: Article

References (41)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
2. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and ''preclinical'' Alzheimer's disease. Ann Neurol 45:358-368.
3. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332.
4. Dickson DW, et al. (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 13:179-189.
5. Bennett DA, et al. (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837-1844.
6. Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
7. Ikonomovic MD, et al. (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:1630-1645.
8. Lopresti BJ, et al. (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46:1959-1972.
9. Mintun MA, et al. (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67:446-452.
10. Rowe CC, et al. (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718-1725.
11. Aizenstein HJ, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65:1509-1517.
12. Forsberg A, et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456-1465.
13. Strittmatter WJ, et al. (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977-1981.
14. Corder EH, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 261:921-923.
15. Farrer LA, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzhei-mer Disease Meta Analysis Consortium. JAMA 278:1349-1356.
16. Coon KD, et al. (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68:613-618.
17. Reiman EM, et al. (1996) Preclinical evidence of Alzheimer's disease in persons ho-mozygous for the -4 allele for apolipoprotein E. N Engl J Med 334:752-758.
18. Reiman EM, Caselli RJ, Alexander GE, Chen K (2001) Tracking the decline in cerebral glucose metablolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res 1:194-206.
19. Reiman EM, et al. (2001) Declining brain activity in cognitively normal apolipoprotein E -4 heterozygotes: A foundation for using positron emission tomography to effi-ciently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98:3334-3339.
20. Reiman EM, et al. (2005) Correlations between apolipoprotein E -4 gene dose and brain imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102:8299-8302.
21. Reiman EM, et al. (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101:284-289.
22. Klunk WE, et al. (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174-6184.
23. Reiman EM, et al. (2008) Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage 40:1214-1221.
24. Reiman EM, Langbaum JBS (in press) in Imaging and the Aging Brain , eds. Jagust WJ, D'Esposito M (Oxford Univ Press, New York).
25. Schmechel DE, et al. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:9649-9653.
26. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
27. Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM (2002) Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv 2:363-375.
28. Koistinaho M, et al. (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10:719-726.
29. Jiang Q, et al. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58:681-693.
30. Risner ME, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254.
31. Greenberg SM, et al. (2008) Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol 64:587-591.
32. Johnson KA, et al. (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62:229-234.
33. Fagan AM, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 59:512-519.
34. Fagan AM, et al. (2007) Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343-349.
35. Sunderland T, et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol Psychiatry 56:670-676.
36. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545-548.
37. Folstein MF, Folstein SE, McHugh PR (1975) ''Mini-mental state'': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
38. Winblad B, et al. (2004) Mild cognitive impairment: Beyond controversies, towards a consensus. Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256:240-246.
39. Price JC, et al. (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528-1547.
40. Tzourio-Mazoyer N, et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289.
41. Talairach J, Tournoux P (1988) Co-Planar Stereotaxic Atlas of the Human Brain (Thieme, New York).